Axsome Therapeutics Shareholders Approve Key Proposals at Meeting

Axsome Therapeutics ( (AXSM) ) just unveiled an announcement.

At the 2025 Annual Meeting of Stockholders held on June 6, Axsome Therapeutics presented four proposals, all of which were approved by the shareholders. These included the election of a Class I director, approval of the 2025 Long-Term Incentive Plan, ratification of Deloitte & Touche LLP as the independent auditor for 2025, and a non-binding advisory vote on executive compensation. The approval of these proposals reflects strong shareholder support and positions the company for continued strategic growth and governance stability.

The most recent analyst rating on (AXSM) stock is a Buy with a $175.00 price target. To see the full list of analyst forecasts on Axsome Therapeutics stock, see the AXSM Stock Forecast page.

Spark’s Take on AXSM Stock

According to Spark, TipRanks’ AI Analyst, AXSM is a Neutral.

Axsome Therapeutics shows promising growth prospects with strong revenue increases and pipeline advancements. However, financial challenges, including ongoing losses and cash flow issues, weigh heavily on the overall score. The recent loan agreement and positive technical indicators provide some support, but regulatory hurdles and profitability concerns remain significant risks.

To see Spark’s full report on AXSM stock, click here.

More about Axsome Therapeutics

Axsome Therapeutics, Inc. operates in the pharmaceutical industry, focusing on developing therapies for central nervous system disorders. The company is known for its innovative treatments aimed at addressing unmet medical needs in this sector.

Average Trading Volume: 707,796

Technical Sentiment Signal: Buy

Current Market Cap: $5.51B

Find detailed analytics on AXSM stock on TipRanks’ Stock Analysis page.